YmAbs Therapeutics (YMAB)
(Delayed Data from NSDQ)
$14.71 USD
-0.13 (-0.88%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $14.68 -0.03 (-0.20%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth C Momentum D VGM
Earnings News For YMAB
-
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Tops Revenue Estimates
-
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
-
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline
-
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
-
Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
-
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
-
Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
-
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates
-
Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance
-
Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know
-
Y-mAbs Therapeutics, Inc. (YMAB) Surpasses Q4 Earnings and Revenue Estimates
-
Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments
-
Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
-
YmAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Tops Revenue Estimates
-
Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
-
YmAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Lags Revenue Estimates
-
YmAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Lags Revenue Estimates
-
Earnings Preview: YmAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline
-
YmAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Misses Revenue Estimates
-
Earnings Preview: YmAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline
-
YmAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Misses Revenue Estimates
-
YmAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
-
YmAbs Therapeutics, Inc. (YMAB) Surpasses Q1 Earnings Estimates